Drug Combination Details
| General Information of the Combination (ID: C87745) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | Oxaliplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colon cancer
[ICD-11: 2B90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | LEF1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | TCF7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | ||
| In-vivo Model | SW480 cells were subcutaneously injected into the back of the mice (2*106 cells in 200 mL of medium). | |||||
| Experimental
Result(s) |
Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo. DNA Cell Biol. 2014 Jul;33(7):418-25. | |||
